Tag Archives: biib

Biogen, Thermo Reports Disappoint; Abbott Accelerates

Big biotech Biogen Idec (BIIB) led a passel of medical firms in reporting Q3 earnings early Wednesday, but Biogen stock was down nearly 8% in early trading on the stock market today as sales of its lead drug disappointed investors. Earlier, Biogen stock touched a five-month low of 290. Biogen’s Q3 earnings rose 61% over the year-earlier quarter to $3.80 a share, beating analysts’ estimates by 34 cents. Sales rose 37% to $2.5 billion, in line with

Biogen Leads 5 Top Biotech Stocks As Earnings Loom

With the market in a new confirmed rally, investors should pay close attention to leading stocks for new buying opportunities. Biogen Idec (BIIB) and other medical companies held up well during the correction and have been leaders this week. Biogen is one of ten pharmaceutical companies featured on today’s IBD Big Cap Screen of the Day. The screen features institutional-quality stocks that are highly liquid and have excellent fundamentals. The

Celgene, Alexion Among 4 IBD 50 Medicals To Report

While the market still looks bearish, top-rated medical stocks including Biogen Idec and Alexion have remained strong as demand for new treatments and breakthroughs overcomes investor skittishness elsewhere. The latest IBD 50 list includes four thriving medical stocks that will report quarterly results this week. The outlook for all of them is healthy revenue and earnings growth vs. the same quarter a year ago. Biotech drugmaker Biogen Idec (BIIB)